Dare Bioscience Investor Presentation Deck
Daré Bioscience: A Compelling Opportunity
1
2
3
4
5
Meaningful market potential for differentiated products
First-line or first-in-category product opportunities across the portfolio
Diverse pipeline with independent outcomes
One FDA-approved product and several clinical development stage candidates
utilizing different APIs and targeting different indications
505(b)(2) FDA pathway planned for most candidates
Use of well-characterized APIs expected to mitigate development risk, time,
and cost- - non-new molecular entities have a 23% probability of success of
advancing from Phase 1 to approval and a 67% likelihood of approval for
Phase 3 to approval, versus 6% and 38% for new molecular entities,
respectively¹
Multiple novel delivery platforms
Persistent unmet needs require creative new approaches designed for her;
Novel delivery platforms allow for first-in-category potential with well
characterized APIs
Commercial value in women's health evidenced by differentiated brands and
recent transformational pharma transactions
1- https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-
%20BIO,%20Biomedtracker,%20Amplion%202016.pdf
Program Milestones in 2022*
include a product launch, data
readout, and Phase 3 investigator
meeting
XACIATOTM (clindamycin phosphate) vaginal gel, 2%
(f/k/a DARE-BV1)
Commercial launch in the U.S. in 4Q 2022
Ovaprene® (hormone-free monthly contraception)
Pivotal Phase 3 study investigator meeting
12/2022; recruitment initiation mid-2023*
DARE-VVA1 (vaginal atrophy treatment for women
with breast cancer)
Phase 1/2 study topline data during 4Q-2022
Sildenafil Cream, 3.6% (female sexual arousal
disorder)
Phase 2b study enrollment expected to complete
4Q-2022
* currently anticipated timing
7View entire presentation